QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:DTIL

Precision BioSciences - DTIL Stock Forecast, Price & News

$1.65
+0.12 (+7.84%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.52
$1.66
50-Day Range
$1.15
$2.09
52-Week Range
$1.11
$14.38
Volume
1.55 million shs
Average Volume
1.70 million shs
Market Capitalization
$102.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.20

Precision BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
809.1% Upside
$15.00 Price Target
Short Interest
Healthy
1.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
-0.85mentions of Precision BioSciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Growing
From ($1.63) to ($1.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

361st out of 1,108 stocks

Biological Products, Except Diagnostic Industry

56th out of 175 stocks

DTIL stock logo

About Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences Price Performance

Shares of NASDAQ:DTIL opened at $1.53 on Wednesday. The firm has a 50-day simple moving average of $1.54 and a 200-day simple moving average of $2.61. The company has a quick ratio of 4.61, a current ratio of 4.61 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $95.13 million, a price-to-earnings ratio of -2.28 and a beta of 1.58. Precision BioSciences has a 52 week low of $1.11 and a 52 week high of $14.38.

Precision BioSciences (NASDAQ:DTIL - Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.03). Precision BioSciences had a negative net margin of 39.10% and a negative return on equity of 44.19%. During the same quarter last year, the company posted $0.36 earnings per share. On average, equities analysts predict that Precision BioSciences will post -1.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on DTIL. William Blair lowered Precision BioSciences from an "outperform" rating to a "market perform" rating in a report on Thursday, June 9th. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Precision BioSciences in a report on Thursday, June 23rd. BMO Capital Markets began coverage on shares of Precision BioSciences in a report on Thursday, June 16th. They set an "outperform" rating and a $7.00 price objective on the stock. Finally, The Goldman Sachs Group reduced their price target on shares of Precision BioSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $15.00.

Insider Activity at Precision BioSciences

In related news, CFO John Alexander Kelly acquired 33,784 shares of the stock in a transaction on Wednesday, June 22nd. The shares were bought at an average price of $1.50 per share, with a total value of $50,676.00. Following the completion of the purchase, the chief financial officer now owns 117,701 shares of the company's stock, valued at approximately $176,551.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO John Alexander Kelly acquired 33,784 shares of the business's stock in a transaction that occurred on Wednesday, June 22nd. The stock was purchased at an average cost of $1.50 per share, for a total transaction of $50,676.00. Following the completion of the transaction, the chief financial officer now owns 117,701 shares in the company, valued at $176,551.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Derek Jantz sold 18,849 shares of Precision BioSciences stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $2.06, for a total transaction of $38,828.94. Following the transaction, the insider now directly owns 4,055,174 shares in the company, valued at $8,353,658.44. The disclosure for this sale can be found here. Insiders own 8.50% of the company's stock.

Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Stock News Headlines

See More Headlines
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Company Calendar

Last Earnings
8/08/2022
Today
8/10/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+821.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-30,600,000.00
Pretax Margin
-39.10%

Debt

Sales & Book Value

Annual Sales
$115.53 million
Book Value
$1.50 per share

Miscellaneous

Free Float
56,891,000
Market Cap
$102.59 million
Optionable
Not Optionable
Beta
1.58

Key Executives

  • Mr. Michael Amoroso (Age 44)
    Pres, CEO & Director
    Comp: $876.24k
  • Dr. Derek Jantz Ph.D. (Age 46)
    Co-Founder, Chief Scientific Officer & Director
    Comp: $597.38k
  • Mr. John Alexander Kelly (Age 55)
    Chief Financial Officer
    Comp: $691.14k
  • Dr. Jefferson J. Smith Ph.D.
    Co-Founder & CTO
  • Mr. Shane Barton (Age 51)
    VP, Corp. Controller & Principal Accounting Officer
  • Mei Burris
    Director of Investor Relations & Fin.
  • Mr. Dario Scimeca (Age 47)
    Gen. Counsel & Sec.
  • Mr. Bruce Stevens
    VP of Quality & Compliance
  • Ms. Heather King
    Director of Marketing Communications & PR
  • Maurissa Messier
    Sr. Director of Corp. Communications













DTIL Stock - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DTIL shares.
View DTIL analyst ratings
or view top-rated stocks.

What is Precision BioSciences' stock price forecast for 2022?

6 brokers have issued 1-year price targets for Precision BioSciences' stock. Their DTIL share price forecasts range from $2.00 to $26.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 828.8% from the stock's current price.
View analysts price targets for DTIL
or view top-rated stocks among Wall Street analysts.

How have DTIL shares performed in 2022?

Precision BioSciences' stock was trading at $7.40 on January 1st, 2022. Since then, DTIL stock has decreased by 78.2% and is now trading at $1.6150.
View the best growth stocks for 2022 here
.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 1,940,000 shares, a decline of 64.3% from the June 30th total of 5,440,000 shares. Based on an average daily volume of 2,930,000 shares, the short-interest ratio is currently 0.7 days.
View Precision BioSciences' Short Interest
.

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our DTIL earnings forecast
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) released its quarterly earnings results on Monday, August, 8th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.03. Precision BioSciences had a negative trailing twelve-month return on equity of 44.19% and a negative net margin of 39.10%. During the same quarter last year, the business posted $0.36 earnings per share.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different retail and institutional investors. Top institutional investors include Moloney Securities Asset Management LLC (0.87%), Curi Wealth Management LLC (0.65%), Lynwood Capital Management Inc. (0.59%), Allworth Financial LP (0.23%) and Connor Clark & Lunn Investment Management Ltd. (0.16%). Insiders that own company stock include Alan List, Christopher Heery, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane and Vince Craig Hopkin.
View institutional ownership trends
.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $1.62.

How much money does Precision BioSciences make?

Precision BioSciences (NASDAQ:DTIL) has a market capitalization of $100.41 million and generates $115.53 million in revenue each year. The company earns $-30,600,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does Precision BioSciences have?

The company employs 198 workers across the globe.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The official website for the company is www.precisionbiosciences.com. The company can be reached via phone at (919) 314-5512 or via email at jwong@bplifescience.com.

This page (NASDAQ:DTIL) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.